Sapna Srivastava's Disposal of Tourmaline Bio Shares and Stock Options

On October 28, 2025, Sapna Srivastava, a director of Tourmaline Bio, Inc., disposed of 518 shares of common stock and several employee stock options as part of a merger agreement with Novartis AG. The common stock was tendered for $48.00 per share, while the stock options were canceled and converted into cash based on the difference between the merger consideration and the exercise price of the options. This transaction was executed pursuant to the merger agreement dated September 8, 2025, which resulted in the acquisition of all outstanding shares of Tourmaline Bio by Novartis AG.